InnoCare Pharma (09969) has completed the share registration process for its 2023 STAR Market restricted stock incentive plan, according to a company announcement. The Shanghai branch of China Securities Depository and Clearing Corporation issued the Securities Change Registration Certificate confirming the fulfillment of requirements under regulations from the China Securities Regulatory Commission, Shanghai Stock Exchange, and ChinaClear. This milestone covers both the second vesting period for initially granted shares and the first vesting period for reserved shares. A total of 2.077 million A-shares will be released from trading restrictions and enter circulation on July 18, 2025. The transaction finalizes the equity registration procedures for this phase of the compensation program.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.